Evaluation morphofunctional state of broiler chickens body's under the applica-tion of various doses of Combiiod
Authors: Zhyla M. I. , Pyatnychko O. M. , Kotsyumbas H. I. , Shkodyak N. V. , Stronskyi Yu. S. , Palonko R. I. 
Published: May 2024

One of the key and mandatory prerequisites for the creation and approbation of new veterinary preparations, both in the context of national legislation and the requirements of the International Community for Registration of Veterinary Medicines, is clinical studies in compliance with the provisions of “Good clinical practice” (GCP). This primarily concerns medicines with a new substance, pharmacology, and efficiency, which have not yet been studied. The technology of growing poultry requires the use of veterinary drugs not only for the prevention of infectious diseases but also for the improvement of metabolic functions and correction of the body’s resistance. One of the priority tasks is to ensure the complete work of the digestive system since it depends on the body's absorption of the nutrients required for the growth of poultry. Among poultry farms, there is considerable interest in drugs with antibacterial, general stimulating action, and coccidiostatics, especially those that do not have an elimination period. The company “Brovafarma” LLC has developed a new form of drug based on Povidone-iodine and sodium selenite for oral use of poultry for the treatment and prevention of diseases caused by bacteria, viruses, myxomycetes, protozoa organisms sensitive to iodine, and for metabolic disorders. That is why the purpose of our experimental studies was to study the safety of a new veterinary drug “Combiiod”, a “solution for oral use”, for healthy broiler chickens. According to the results of the study, it was found that the feeding of the drug “Combiiod” chickens-broiler at a therapeutic dose (0.2 ml per 1 liter of water) and in 5 multiple therapeutic doses (1.0 ml per 1 liter of water) within 5 days for two courses with weekly interval was well tolerated by the experimental poultry, did not cause death and violation of the morphofunctional state of broiler chickens bodies. In the blood of broiler chickens, which received the drug “Combiiod” at the therapeutic dose, most studied morphological and biochemical indicators were within the physiological values for this type of poultry. They did not differ significantly from the indicators of the control group. In the serum of poultry, which used 5 multiple therapeutic doses, a significant decrease in the content of erythrocytes, hemoglobin, and uric acid and an increase in the activity of alanine aminotransferase (ALT), alkaline phosphatase (ALP), and the content of bile acids were revealed. Analyzing the coefficients of individual internal organs and mass of broiler chickens, no significant difference in indicators between experimental and control groups has been noted. Pathomorphological examination has not established a violation of the morphofunctional state of broiler chickens ’ bodies, which received a therapeutic dose. Histological changes in the structure of the kidneys, liver, and heart, which were reversed, were found in the poultry that received 5 multiple therapeutic doses of the drug.